NANOVIRICIDES, INC. 8-K

What Happened

• NanoViricides, Inc. announced on July 17, 2026 that it entered into an At Market Issuance Sales Agreement with D. Boral Capital LLC to offer and sell shares of its common stock from time to time in an "at the market" (ATM) offering.
• The offering will be made under the company’s shelf Registration Statement on Form S-3 (File No. 333-296550) (initially filed June 5, 2026 and declared effective June 15, 2026); a prospectus supplement was filed the same day as the sales agreement.
• The sales agent will sell shares on the NYSE American or other trading markets and may use privately negotiated transactions with the company’s consent; the company filed the Sales Agreement (Exhibit 1.1) and a legal opinion (Exhibit 5.1) with the 8-K.

Key Details

• Date of agreement: July 17, 2026.
• Sales agent: D. Boral Capital LLC.
• Commission: 2.0% of gross proceeds for shares sold through the sales agent.
• Offering mechanics: ATM sales on public markets or other lawful methods; each sale will be initiated by a placement notice from NanoViricides. The 8-K does not state a specific maximum number of shares or target offering amount.

Why It Matters

• This ATM agreement gives NanoViricides a flexible, on-demand way to raise capital under its effective S-3 registration, enabling sales when market conditions are favorable.
• Any shares sold will increase the company’s shares outstanding and dilute existing shareholders proportionally; investors should watch for future sale notices and prospectus updates to see timing, amounts, and intended use of proceeds.
• The 2% placement fee and the existence of a filed prospectus supplement and legal opinion are concrete, immediate facts investors can verify in the 8-K and related documents.